ArticleTransboundary and emerging diseases2026
Emergence of Recombinant Myxoma Virus in Algerian Farmed Rabbits: Molecular and Phylogenetic Evidence.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Simultaneous detection of classic and natural recombinant myxoma virus strains in European brown hare population in West Hungary.Frontiers in veterinary science · 2026Article
- Emergence of Recombinant Myxoma Virus in Algerian Farmed Rabbits: Molecular and Phylogenetic Evidence.Transboundary and emerging diseases · 2026Article
- Outbreak of an Emerging Recombinant of Myxoma Virus ha-MYXV in European Brown Hares (Lepus europaeus) in Austria.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxomatosis is a severe viral disease of lagomorphs that has recently seen the emergence of a recombinant myxoma virus (MYXV). Data from Africa remain scarce. Here we report the first confirmed detection and genomic characterization of a recombinant MYXV in Algeria. Two domestic rabbits from a backyard smallholding in El Affroun (Blida province) were presented on 19 October 2022 with classical signs of myxomatosis, including marked facial edema, severe mucopurulent blepharoconjunctivitis, and respiratory involvement. Necropsy and histopathology showed lesions typical of myxomatosis (epithelial hyperplasia with ballooning degeneration, intracytoplasmic inclusions, ulceration, stromal expansion by myxoma cells, and vascular hyperemia and leukostasis). MYXV DNA was detected in multiple tissues from both animals, and virus isolation on RK-13 cells produced cytopathic effects (CPEs) by days 5-7 postinoculation. The Algerian MYXV sequence showed >99.9% nucleotide identity to the MYXV Toledo strain (GenBank Accession Number MK836424.1). Phylogenetic analysis placed the Algerian strain within the recombinant ha-MYXV cluster, between earlier Spanish sequences (2018) and more recent Northern European sequences (2024), with the most recent common ancestor estimated around January 2017 (95% HPD July 2015-May 2018). These findings extend the known range of recombinant MYXV beyond Europe and highlight introduction risks at the pet-farm-wildlife interface in North Africa. We recommend strengthened vaccination of pet and farmed rabbits, pragmatic biosecurity in smallholdings, and targeted surveillance of hare populations to clarify sources and transmission routes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.